Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Evaluation Of FDA District Offices Under MRA To Begin By Feb. 2001

This article was originally published in The Tan Sheet

Executive Summary

FDA expects European regulators to begin assessing agency district offices in the next six to eight months, Office of Regulatory Affairs Regional Director Deborah Ralston told a June 5 Food & Drug Law Institute meeting in Washington, D.C.

You may also be interested in...

International Harmonization Should Focus On Post-Marketing Activities - HRG

International harmonization efforts should include an emphasis on post-marketing activities, Public Citizen's Health Research Group Deputy Director Peter Lurie, MD, commented at an FDA public meeting on the future of the International Conference on Harmonization May 16.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts